Which one of the following is not a Novel biomarker of acute kidney injury ?
**Core Concept**
Acute kidney injury (AKI) is a complex clinical syndrome characterized by a rapid decline in kidney function, often resulting in increased morbidity and mortality. Novel biomarkers of AKI have been identified to aid in early detection and diagnosis, supplementing traditional markers like serum creatinine.
**Why the Correct Answer is Right**
The correct answer is **Neutrophil Gelatinase-Associated Lipocalin (NGAL)**, which is indeed a novel biomarker of AKI. NGAL is a protein that is rapidly upregulated in the kidneys in response to ischemic injury and is detectable in the urine within hours of AKI onset. Its levels have been shown to correlate with the severity of AKI and may predict the development of AKI in high-risk patients.
**Why Each Wrong Option is Incorrect**
* **Option A:** Liver-type Fatty Acid Binding Protein (L-FABP) is actually a novel biomarker of AKI, which is released from damaged kidney cells and can be detected in the urine.
* **Option B:** Kidney Injury Molecule-1 (KIM-1) is another novel biomarker of AKI that is upregulated in response to kidney injury and has been shown to predict AKI in various clinical settings.
* **Option C:** Interleukin-18 (IL-18) is also a novel biomarker of AKI that is released from damaged kidney cells and has been shown to predict AKI in patients undergoing cardiac surgery.
**Clinical Pearl / High-Yield Fact**
Novel biomarkers like NGAL, L-FABP, KIM-1, and IL-18 have the potential to revolutionize the early detection and diagnosis of AKI, allowing for timely intervention and improved patient outcomes. These biomarkers may also aid in the prediction of AKI in high-risk patients, enabling targeted preventative strategies.
**Correct Answer:** D. Neutrophil Gelatinase-Associated Lipocalin (NGAL)